Association of Pancreatic Fatty Infiltration With Pancreatic Ductal Adenocarcinoma

Mika Hori, PhD1, Mami Takahashi, PhD2, Nobuyoshi Hiraoka, MD, PhD3, Taiki Yamaji, MD, PhD, MPH1, Michihiro Mutoh, MD, PhD5, Rikako Ishigamori, PhD3, Koh Furuta, MD, PhD6, Takuji Okusaka, MD, PhD7, Kazuaki Shimada, MD, PhD8, Tomoo Kosuge, MD, PhD6, Yae Kanai, MD, PhD2 and Hitoshi Nakagama, MD, DMSc1,5

OBJECTIVES: Fatty infiltration (FI) in the pancreas is positively correlated with high body mass index (BMI) or obesity, and the prevalence of diabetes mellitus (DM), which are well-known risk factors of pancreatic cancer. However, the association of FI in the pancreas with pancreatic cancer is unclear. Recently, we have shown that Syrian golden hamsters feature FI of the pancreas, the severity of which increases along with the progression of carcinogenesis induced by a chemical carcinogen. To translate the results to a clinical setting, we investigated whether FI in the pancreas is associated with pancreatic cancer in a series of patients who had undergone pancreatoduodenectomy.

METHODS: In the series, we identified 102 cases with pancreatic ductal adenocarcinoma (PDAC) and 85 controls with cancers except for PDAC. The degree of FI was evaluated histopathologically from the area occupied by adipocytes in pancreas sections, and was compared between the cases and controls.

RESULTS: The degree of FI in the pancreas was significantly higher in cases than in controls (median 26 vs. 15%, \(P < 0.001\)) and positively associated with PDAC, even after adjustment for BMI, prevalence of DM and other confounding factors (odds ratio (OR), 6.1; \(P < 0.001\)). BMI was identified as the most significantly associated factor with FI in the pancreas.

CONCLUSIONS: There is a positive correlation between FI in the pancreas and pancreatic cancer.

Clinical and Translational Gastroenterology (2014) 5, e53; doi:10.1038/ctg.2014.5; published online 13 March 2014

Subject Category: Pancreas and Biliary Tract

INTRODUCTION

Pancreatic cancer is one of the most lethal human cancers with a 5-year survival rate of <5% in both Japan and the United States.1 Thus, the development of useful predictive markers for individuals with a high risk of pancreatic cancer would be of great help in detecting pancreatic cancer at its early stages, and might contribute to a significant reduction of mortality. Epidemiological studies have shown that a family history of pancreatic cancer, cigarette smoking, age, obesity, and diseases such as chronic pancreateitis and diabetes mellitus (DM) increase the risk of pancreatic cancer.2–4 A few pathological studies of patients with pancreatic cancer have demonstrated fatty infiltratation (FI) in the pancreas parenchyma.5,6 FI in the pancreas is positively correlated with age, body mass index (BMI), and a history of DM.7–9

Recently, we have shown that in Syrian golden hamsters, which exhibit a substantial age-related increase of hypertriglyceridemia and FI in the pancreas, there is further progression of pancreatic FI and carcinogenesis upon treatment with a carcinogen, N-nitrosobis(2-oxopropyl) amine (BOP), while the animals are fed a high-fat diet (HFD).10 Therefore, we hypothesized that FI in the pancreas accompanied by hypertriglyceridemia might be associated with pancreatic cancer in both humans and experimental animals.

In the present case–control study, we examined whether FI in the pancreas is associated with pancreatic ductal adenocarcinoma (PDAC) in humans, independently of several other suggested risk factors for pancreatic cancer, such as obesity and DM.

METHODS

Patients and samples. Between January 2004 and December 2010, 367 patients underwent pancreatoduodenectomy for PDAC at the National Cancer Center Hospital, Japan. Among them, 102 were considered to be appropriate for the present study on the basis of the criteria detailed later. As controls, we used non-cancerous pancreas tissues from 85 patients who had undergone pancreatoduodenectomy for cancer, except for PDAC; these included 46 patients with distal bile duct cancer, 33 with cancer of the ampulla of Vater, 4 with gallbladder cancer, and 2 with duodenal cancer. DM was clinically diagnosed at the referring hospitals, using criteria of fasting blood glucose level ≥126 mg/dl and HbA1c ≥6.1%, before the patients visited our hospital to resect pancreatic cancer. BMI was calculated when the patients were admitted to our hospital. The use of each individual’s material for analysis in the

1Division of Cancer Development System, National Cancer Center Research Institute, Tokyo, Japan; 2Central Animal Division, National Cancer Center Research Institute, Tokyo, Japan; 3Division of Molecular Pathology, National Cancer Center Research Institute, Tokyo, Japan; 4Epidemiology and Prevention Division, Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo, Japan; 5Division of Cancer Prevention Research, National Cancer Center Research Institute, Tokyo, Japan; 6Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan; 7Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan and 8Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, Tokyo, Japan. Correspondence: Hitoshi Nakagama, MD, DMSc, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
E-mail: hnakagam@ncc.go.jp
Received 1 November 2013; revised 6 January 2014; accepted 15 January 2014
present study was approved by the Ethics Review Committee of the National Cancer Center (2010-088). The materials are from patients who had given general consent for the research use of their leftover samples, and all clinical investigations were conducted in accordance with the principles of the Declaration of Helsinki.

Pathological examination. PDACs were examined pathologically and classified according to the World Health Organization classification and TNM classification.11,12 Surgically resected specimens were fixed in 10% formalin, and the pancreas heads were cut horizontally into serial slices 5 mm thick. In order to evaluate FI appropriately, we conducted a preliminary study to select a target area of pancreas parenchyma in 16 cases of PDAC. As FI is easily affected by any type of pancreatic tissue associated with cancer infiltration, including obstructive pancreatitis, we selected the FI area for measurement, avoiding any primary and/or secondary effect caused by cancer infiltration (Supplementary Figure S1 online). Thus, pancreatitis patients were ruled out from the FI evaluation. First, we selected anterior and cranial areas of the pancreas near the duodenum that correspond to the dorsal pancreas during organogenesis. Second, we chose areas of the pancreas near the ampulla of Vater if the former area was affected by cancer infiltration. If both of these areas were affected by cancer infiltration, such cases were excluded from the study. Thus, we selected one section containing non-tumorous pancreatic tissue and confirmed whether it fulfilled the above conditions. Then, FI areas were measured quantitatively as the percentage of area infiltrated by adipocytes relative to the total area on the section was calculated using the WinROOF image analysis software package (Mitani Corp, Tokyo, Japan). The reproducibility of this quantitation method was checked preliminarily by comparing the FI area of one section with another section derived from tissue immediately adjacent to the former. The difference between the two FI area values measured in 16 pairs of sections was 5.6% on average.

Serum sample collection and assays. Peripheral blood was collected from each patient at the time of the hospital visit prior to treatment, and blood sugar, HbA1c, and serum levels of total cholesterol (TC), high-density lipoprotein (HDL), amylase, CEA, and CA19-9 were measured by participants provided by the National Cancer Center Biobank, Japan, was stored at −20°C. Serum adiponectin, leptin and insulin growth factor-I (IGF-I) (R&D Systems, Inc., Minneapolis, MN, USA), apolipoprotein A-II (apoA-II) (Assay pro, St Charles, MO, USA), insulin (Millipore, Billerica, MA, USA), and serum amyloid A (SAA; Invitrogen, Camarillo, CA, USA) were measured using enzyme-linked immunosorbent assay kits in accordance with the manufacturers’ instructions. The levels of serum triglycerides (TGs), HDL, and gamma-glutamyltransferase (GGT) were analyzed using the FUJI Dri-Chem system (Fuji Film, Tokyo, Japan).

Statistical analysis. The cases and controls were classified into three subgroups, <10%, 10–20%, and ≥20%, according to the area of FI. The cutoff points of 10 and 20 were nearly equal to the tertile cutoff points in the controls, namely 9.5 and 20.4. An unconditional logistic regression model was used to estimate odds ratios (ORs) and their 95% confidence intervals (CIs) of PDAC according to the three categories of FI in the pancreas, the lowest value being used as a reference. Two-sided P values <0.05 were considered to indicate statistical significance. All statistical analyses were carried out using the Statistical Analysis System (SAS), version 9.1 software package (SAS Institute, Cary, NC, USA) by a statistician (T.Y.).

RESULTS

Patient characteristics. Among 102 cases, one was classified as stage IB, 27 as stage IIA, 65 as stage IIB, and 9 as stage IV. The characteristics of the case and control patients are summarized in Table 1. Controls were older than cases (P = 0.001), and there was a male predominance in both groups. The known risk factors for PDAC were compared between cases and controls. The prevalence of DM (P = 0.03) and family history of pancreatic cancer (P = 0.007) in cases was higher than in controls. The serum apoA-II level was shown to be lower in cases than in controls (P = 0.02), as reported previously, in comparison with healthy subjects. CEA (P = 0.04) and CA19-9 (P < 0.001), serum tumor markers for PDAC, were also significantly higher in cases than in controls. Meanwhile, serum levels of GGT (P < 0.001), which are associated with liver and biliary disorders, were higher in controls than in cases.

Association of FI in the pancreas with PDAC. In the human pancreas, adipocytes were observed to accumulate in the area between pancreatic lobules (interlobular fat), especially around great vessels, or to be scattered in the lobules (intralobular fat), as shown in Figure 1. The distribution pattern of FI in some patients was similar to that observed in hamster pancreas.10 In this study, FI in the pancreas was defined as the sum of the areas showing any types of FI in the pancreas parenchyma. Table 1 shows that the area of FI in the pancreas was significantly greater in cases than in controls (median 26 vs. 15%, P = 0.001). Types of differentiation and stages of PDACs were not associated with the degree of FI (data not shown).

Table 2 shows the association between the area of FI in the pancreas and PDAC. A significantly higher OR for PDAC was observed according to the area of FI in the pancreas (P < 0.001). Adjusted for sex, age, BMI, history of DM, and family history of pancreatic cancer, confounding factors for pancreatic cancer, ORs for PDAC showed an increasing trend according to the area of FI (P < 0.001). Even when patients with a BMI > 25 kg/m², a history of DM, and a family history of pancreatic cancer were excluded, positive associations between the degree of FI in the pancreas and PDAC were observed (P < 0.001 overall).

The factors associated with FI. The characteristics of the study participants were examined in relation to the degree of FI of the pancreas in controls and cases and are shown in Supplementary Tables 1 and 2, respectively. BMI and age were positively correlated with the area of FI of the pancreas.
Table 1  Selected characteristics of study subjects

| Characteristic                                      | Cases (n = 102) | Controls (n = 85) | P* |
|-----------------------------------------------------|-----------------|-------------------|----|
| **Categorical variables, n (%)**                    |                 |                   |    |
| FI in the pancreas ≥ 20%                            | 64 (62.7)       | 30 (35.2)         | < 0.001 |
| Male                                                | 60 (58.8)       | 60 (70.5)         | 0.12 |
| Ever smoking                                        | 53 (51.9)       | 42 (49.4)         | 0.77 |
| Frequent drinking (5–7 times/week)                 | 34 (33.3)       | 31 (36.9)         | 0.85 |
| DM                                                  | 30 (29.4)       | 14 (16.4)         | 0.03 |
| Hypertension                                        | 36 (35.2)       | 27 (31.7)         | 0.64 |
| Hyperlipidemia                                      | 7 (6.8)         | 10 (11.7)         | 0.30 |
| Family history of PC                                | 11 (10.7)       | 1 (1.1)           | 0.007 |
| **Continuous variables, median (IQR)**              |                 |                   |    |
| FI in the pancreas, %                               | 25.8 (14.2–40.9) | 15.0 (7.7–24.8) | < 0.001 |
| Age, years                                          | 63.5 (56–69)    | 68.0 (63–73)      | 0.001 |
| BMI, kg/m²                                          | 22.4 (20.3–24.3) | 22.7 (20.7–24.2) | 0.95 |
| Blood sugar, mg/dl                                 | 114.0 (100–141) | 106.0 (93–119)    | 0.002 |
| HbA1c, %                                            | 5.5 (5.1–6.4)   | 5.1 (4.7–5.5)     | < 0.001 |
| TC, mg/dl                                           | 189.0 (162–221) | 195.0 (169–227)   | 0.31 |
| HDL, mg/dl                                         | 52.0 (43–62)    | 52.0 (42–67)      | 0.47 |
| TG, mg/dl                                          | 149.0 (109–209) | 155.0 (117–210)   | 0.38 |
| Apo A-II, µg/ml                                     | 219.3 (136.7–397.5) | 327.3 (174.0–444.4) | 0.02 |
| Adiponectin, µg/ml                                  | 5.4 (3.0–9.6)   | 6.3 (3.2–12.3)    | 0.37 |
| Leptin, ng/ml                                       | 3.2 (2.2–4.6)   | 3.1 (2.4–3.8)     | 0.57 |
| Insulin, µU/l                                       | 3.5 (2.5–5.8)   | 3.7 (2.8–6.4)     | 0.41 |
| IGF-I, ng/ml                                        | 69.7 (53.2–93.5) | 74.1 (54.4–96.4) | 0.69 |
| Amylase, IU/l                                       | 107.0 (75–182)  | 105.0 (83–141)    | 0.55 |
| CEA, ng/ml                                          | 2.6 (1.6–4.1)   | 2.0 (1.3–3.4)     | 0.04 |
| CA19-9, U/ml                                        | 96.0 (46–400)   | 30.0 (16–121)     | < 0.001 |
| SAA, µg/ml                                          | 22.1 (8.93–54.3) | 35.8 (12.7–89.8) | 0.06 |
| GGTT, ng/ml                                         | 105.0 (33–311)  | 339.0 (101–673)   | < 0.001 |

Apo A-II, apolipoprotein A-II; BMI, body mass index; DM, diabetes mellitus; FI, fatty infiltration; GGT, gamma-glutamyltransferase; HDL, high density lipoprotein; IGF-I, insulin growth factor-I; IQR, interquartile range; PC, pancreatic cancer; SAA, serum amyloid A; TC, total cholesterol; TG, triglyceride.

*Based on the Fisher’s exact test for percentage difference and the Wilcoxon rank-sum test for median difference.

Figure 1  Histology of the human pancreas with fatty infiltration. (a, b) Pancreas tissue with moderate to severe FI. Most of the pancreas parenchyma has been replaced by adipocytes, and the remaining pancreas lobules resemble islets surrounded by a fatty lake. Most adipocytes have accumulated interlobularly (arrow in b), but some are scattered within the lobules (arrowhead in b). (c) Pancreas tissue with mild FI. Adipocytes have accumulated around arterioles (arrow), and several adipocytes are scattered within the lobules (arrowhead). (d) Pancreas tissue with minimal FI. Super-low magnification in a, and low magnification in (b to d).
in both cases and controls. In control patients, the serum TG and amylase values were also positively correlated with the area of FI in the pancreas. Meanwhile, the levels of the serum insulin, HbA1c and blood sugar in case patients were positively correlated with the area of FI in the pancreas. To further investigate an association with FI in the pancreas, we conducted a multivariable linear regression analysis in each group, in which the above variables (BMI, serum TG, and amylase values for controls; BMI, serum insulin, HbA1c, and blood sugar for cases), as well as age and sex, were included in one model. After mutual adjustment, a statistically significant association was noted only for BMI (controls, \( P = 0.001 \); cases, \( P = 0.01 \)).

DISCUSSION

Based on epidemiological observation of human pancreatic cancers, FI in the pancreas was suggested to associate with PDAC, independently of known risk factors such as obesity and DM (Supplementary Figure S2). Although we identified BMI, a measurement of obesity, as the most significantly associated factor among several factors related to FI in the pancreas, FI in the pancreas was likely to increase the risk of pancreatic cancer beyond the effect of obesity alone. Some cancers, FI in the pancreas was suggested to associate with BMI, body mass index; CI, confidence interval; DM, diabetes mellitus; FI, fatty infiltration; OR, odds ratio; PC, pancreatic cancer.

Adjusted for sex, age (\( \leq 60, 61–70 \) and \( > 70 \)), past history of DM (yes or no), and family history of PC (yes or no).

Adjusted for sex, age (\( \leq 60, 61–70 \) and \( > 70 \)), past history of DM (yes or no), and family history of PC (yes or no).
death of acinar cells. We agree with their statements that pancreatic fat accumulation is mainly induced by these two factors. In this study, pancreatic FI in cases represents any type of fat accumulation caused by any type of etiology. It has been reported that lipotoxicity caused by a high TG content induces inflammatory responses and necrosis in pancreatic acinar cells in vitro.\textsuperscript{28,29} It has also been shown that c-Myc activity is required for growth and maturation of the exocrine pancreas and for the transdifferentiation of acinar cells into adipocytes in mice.\textsuperscript{30} Thus, pancreas containing scattered adipocytes might be more sensitive to acinar cell damage due to lipotoxicity and other genetic factors, and scattered FI may reflect the acinar cell death or transdifferentiation after the damage.

Some limitations could be pointed out in this study. The major limitation is that it lacked normal healthy controls because pancreatic sections could be obtained only from patients who had undergone pancreatoduodenectomy. A second limitation is that we could not measure FI in more than one pancreatic section, as areas for measuring FI were limited and small because the areas of tumor and secondary inflammation were avoided. Therefore, a future study using a non-invasive method will be required to evaluate FI in a large area/volume of pancreas from healthy and case subjects. Previously, we have reported a case of PDAC that was associated with marked FI in the pancreas, as seen on computed tomography images.\textsuperscript{31} Computed tomography imaging of the pancreas would be a useful approach for accurate evaluation and follow-up of pancreatic FI in normal subjects, as well as in cohort studies. The third limitation is that we did not exclude the areas of pancreas with PanINs from the sections for measuring FI because it is known that PanINs are sometimes found in pancreatic tissue of the elderly, and also that a large number of PanINs with various grades are found in the pancreas of the patients with PDAC. Therefore, it is extremely difficult to measure FI in the pancreas tissue without PanINs, especially in the limited area for measuring FI. The fourth limitation is that BMI could be underestimated in the cases, because weight loss is a very common symptom of patients suffering from pancreatic cancer even though most cases were classified as stage IIA or IIB. The fifth limitation is that there is no validation study. To confirm the observation in the present study, the same study should be repeated with the same methods in another center (hospital/institution). The final limitation is that we cannot distinguish whether FI was a risk factor or a consequence of the cancer. The only way to demonstrate that FI is a risk factor for PDAC is to perform a prospective cohort study to observe whether individuals with fatty pancreas could develop PDAC. For this purpose, we are now trying to establish the methods to evaluate FI in a large area/volume of pancreas by non-invasive method, using computed tomography and magnetic resonance imaging. In addition, studies on pancreatic carcinogenesis using animal models of fatty pancreas would be helpful to elucidate underlying mechanisms.

In conclusion, there is a positive correlation between FI in the pancreas and pancreatic cancer. The development of effective detection methods and/or markers of FI, especially “fatty pancreas” with severe FI, is warranted for mass screening of individuals at high risk of pancreatic cancer at health examinations.

CONFLICT OF INTEREST

Guarantor of the article: Hitoshi Nakagama, MD, DMSc.

Specific author contributions: Mika Hori contributed to the design of the study, acquisition, analysis and interpretation of data, writing and drafting of the manuscript; Mami Takahashi contributed to the conception of the study, development of methodology and data analysis and revision of the manuscript; Nobuyoshi Hiraoka contributed to the histopathological analysis and revision of the manuscript; Taiki Yamaji contributed to the statistical analysis and revision of the manuscript; Michihiro Mutoh contributed to data analysis and revision of the manuscript; Rikako Ishigamori contributed to the histopathological analysis; Koh Furuta contributed to material supports in human serum analysis; Takuji Okusaka contributed to the clinical revision of the manuscript; Kazuaki Shimada contributed to the clinical revision of the manuscript; Tomoo Kosuge contributed to the clinical revision of the manuscript; Yae Kanai contributed to the histopathological analysis; Hitoshi Nakagama contributed to study supervision and revision of the manuscript.

Financial support: This work was supported by: Grants-in-Aid for Cancer Research from the Ministry of Health, Labour, and Welfare of Japan and Management Expenses Grants from the Government to the National Cancer Center (21–2–1, 23-A-4); a grant of the Third-Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labor, and Welfare of Japan; a grant of the Research Grant of the Princess Takamatsu Cancer Research Fund; Grants-in-Aid from the Foundation for Promotion of Cancer Research and the Pancreas Research Foundation of Japan. M. Hori was an Awardee of Research Resident Fellowships from the Foundation for Promotion of Cancer Research (Japan) and from the Third-Term Comprehensive 10-Year Strategy for Cancer Control during the course of the present research.

Potential competing interests: None.

Acknowledgments. The National Cancer Center Biobank is supported by the National Cancer Center Research and Development Fund, Japan.

Study Highlights

**WHAT IS CURRENT KNOWLEDGE**

- Fatty infiltration (FI) in the pancreas is positively correlated with obesity and prevalence of DM.
- The association of FI in the pancreas with pancreatic ductal adenocarcinoma (PDAC) is unclear in humans.

**WHAT IS NEW HERE**

- FI in the pancreas is associated with PDAC development in humans.
- Body mass index (BMI) was identified as the most significantly associated factor with FI in the pancreas.
- FI in the pancreas may increase the risk of PDAC beyond the effect of obesity alone.

1. Maitra A, Huban RH. Pancreatic cancer. *Annu Rev Pathol* 2008; 3: 157–188.
2. Patel AV, Rodriguez C, Bernstein L et al. Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. Cohort. *Cancer Epidemiol Biomarkers Prev* 2005; 14: 459–466.
Fatty Infiltration is Associated With Pancreatic Cancer
Hori et al.

3. Huieley R, Ansary-Moghaddam A, Berrenting de Gonzalez A et al. Type II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005; 92: 2076–2083.

4. Li D, Morris JS, Liu J et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 2009; 301: 2553–2562.

5. Toyama N, Kamiyama H, Suminaga Y et al. Pancreas head carcinoma with total fat replacement of the dorsal exocrine pancreas. J Gastroenterol 2004; 39: 76–80.

6. Makay O, Kazimi M, Aydin U et al. Fat replacement of the malignant pancreatic tissue after neoadjuvant therapy. Int J Clin Oncol 2010; 15: 88–92.

7. Walters MN. Adipose atrophy of the exocrine pancreas. J Pathol Bacteriol 1966; 92: 547–557.

8. Rosso E, Cansell S, Pessaux P et al. The role of “fatty pancreas” and of BMI in the occurrence of pancreatic fistula after pancreatoduodenectomy. J Gastrointest Surg 2009; 13: 1845–1851.

9. Lee JS, Kim SH, Jun DW et al. Clinical implications of fatty pancreas: correlations between fatty pancreas and metabolic syndrome. World J Gastroenterol 2009; 15: 1869–1875.

10. Hori M, Onaya H, Takahashi M et al. Enhancement of carcinogenesis and fatty infiltration in the pancreas in N-nitrosobis(2-oxopropyl) amine-treated hamsters by high fat diet. Pancreas 2011; 40: 1234–1246.

11. Hruban RH, Boffetta P, Hiraoka N et al. Ductal adenocarcinoma of the pancreas. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds). WHO Classification of Tumours IARC: Lyon, France, 2010, pp. 281–291.

12. Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours. Willey-Blackwell, Oxford, UK, 2009.

13. Kovankiyya A, Mittelman SD, Ward A et al. Obesity and fat quantification in lean tissues using three-point Dixon MR imaging. Pediatr Radiol 2009; 35: 601–607.

14. Schwzenzer NF, Machann J, Martinosian P et al. Quantification of pancreatic lipomatosis and liver steatosis by MRI: comparison of in/opposed-phase and spectral-spatial excitation techniques. Invest Radiol 2008; 43: 330–337.

15. Lingvay I, Esser V, Legendre JL et al. Noninvasive quantification of pancreatic fat in humans. J Clin Endocrinol Metab 2009; 94: 4070–4076.

16. Lee SE, Jung JY, Lim CS et al. Measurement of pancreatic fat by magnetic resonance imaging: predicting the occurrence of pancreatic fistula after pancreatoduodenectomy. Ann Surg 2010; 251: 332–336.

17. Mathur A, Zyromski NJ, Pitt HA et al. Pancreatic steatosis promotes dissemination and lethality of pancreatic cancer. J Am Coll Surg 2009; 208: 989–994.

18. Mathur A, Pitt HA, Marine M et al. Fatty pancreas: a factor in postoperative pancreatic fistula. Ann Surg 2007; 246: 1058–1064.

19. Okuya S, Tanabe K, Tanizawa Y et al. Leptin increases the viability of isolated rat pancreatic islets by suppressing apoptosis. Endocrinology 2001; 142: 4827–4830.

20. Hardwick JC, Van Den Brink GR, Offerhaus GJ et al. Leptin is a growth factor for colonic epithelial cells. Gastroenterology 2001; 121: 79–90.

21. Kim SJ, Nian C, McIntosh CH. Activation of lipoprotein lipase by glucose-dependent insulinotrophic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade. J Biol Chem 2007; 282: 8557–8567.

22. Tuszynicz ME, Buncik MC, Pouwels PJ et al. Pancreatic fat content and beta-cell function in men with and without type 2 diabetes. Diabetes Care 2007; 30: 2916–2921.

23. Van Herpen NA, Schrauwen-Hinderling VB. Lipid accumulation in non-adipose tissue and lipotoxicity. Physiol Behav 2008; 94: 231–241.

24. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840–846.

25. Uzdada T, Tsuchiya R, Harada N et al. Ischemic changes in the pancreas of Watanabe heritable hyper-lipidemic (WHHL) rabbits. Int J Pancreatol 1998; 3: 261–272.

26. Watanabe S, Abe K, Arbo Y et al. Changes in the mouse exocrine pancreas after pancreatic duct ligation: a qualitative and quantitative histological study. Arch Histol Cytol 1995; 58: 365–374.

27. Smts MM, van Geenen EJ. The clinical significance of pancreatic steatosis. Nat Rev Gastroenterol Hepatol 2011; 8: 169–177.

28. Navina S, Acharya C, DeLany JP et al. Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity. Sci Transl Med 2011; 3: 107–110.

29. Pinnick KE, Collins SC, Londos C et al. Pancreatic exocrine fat is characterized by adipocyte infiltration and altered lipid composition. Obesity 2008; 16: 522–530.

30. Bonal C, Thorel F, Ait-Lounis A et al. Pancreatic inactivation of c-Myc decreases acinar mass and transdifferentiates acinar cells into adipocytes in mice. Gastroenterology 2009; 136: 309–319.

31. Hori M, Onaya H, Takahashi M et al. Invasive ductal carcinoma developing in pancreas with severe fatty infiltration. Pancreas 2012; 41: 1137–1139.

Clinical and Translational Gastroenterology is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/